Please see table below for details . 87 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 Treatment -related adverse events 3 mg/kg (n = 3) 10 mg/kg (n = 3) 20 mg/kg (n = 7) Total (n = 16) Any Grade Grade 3 Any Grade Grade 3 Any Grade Grade 3 Any Grade Grade 3 Participants with any event** 2 (66.7) 1 (33.3) 1 (33.3) 0 (0.0) 4 (57.1) 2 (28.6) 7 (43.8) 3 (18.8) Anemia 1 (14.3) 1 (14.3) 1 (6.3) 1 (6.3) Bullous pemphigoid 1 (33.3) 1 (6.3) Colitis 1 (14.3) 1 (14.3) 1 (6.3) 1 (6.3) Dermatitis acneiform 1 (33.3) 1 (6.3) Dyspnea exertional*** 1 (14.3) 1 (6.3) Hyperthyroidism 1 (14.3) 1 (6.3) Hypophosphatemia 1 (14.3) 1 (6.3) Hypothyroidism 1 (33.3) 1 (14.3) 2 (12.5) Infusion -related reaction 1 (14.3) 1 (6.3) Keratoacanthoma 1 (14.3) 1 (6.3) Lipase increase 1 (14.3) 1 (14.3) 1 (6.3) 1 (6.3) Nausea 1 (33.3) 1 (6.3) Pruritus 1 (33.3) 1 (6.3) Rash maculo - papular 1 (33.3) 1 (33.3) 2 (12.5) Skin infection 1 (33.3) 1 (33.3) 1 (6.3) 1 (6.3) Vomiting 1 (33.3) 1 (6.3) **There were no treatment -related AEs in the 3 participants treated with 1 mg/kg M7824. ***The differential for this dyspnea was pneumonitis vs. lymphangitic spread of disease (disease progression). 88 Abbreviated Title: Combo Immunotx in HPV Cancers Version Date: 05.12.2023 As of August 2017, > 500 participants have been treated with M7824 across multiple solid tumor expansion cohorts. The safety profile is consistent with other monotherapy checkpoint inhibitors, with the exception of keratoacanthomas and cutaneous squamous cell carcinomas which have occurred in approximately 3- 5% of participants and are well managed with surgical excision. These lesions have not been a criterion for treatment discontinuation, but thus far have all spontaneously regressed following treatment discontinuation. At least 2 instances of nodular regenerative hyperplasia have been observed with the use of this agent. 14.2.2.1 Hemophagocytic lymphohistiocytosis (HLH) HLH/MAS is an inflammatory response which may be related to immune therapy, but the mechanism is poorly understood. This may present with liver function test abnormalities, low blood cell counts, fevers, elevated ferritin and/or elevated triglycerides. HLH may be acquired (secondary), but in the setting of immune therapy we believe it is acquired.